GLP1 Survey
Impact of GLP-1 Drugs on Consumer Eating Habits and Food Industry Trends
HALIFAX, March 26, 2024 — In recent years, the use of GLP-1 receptor agonists, such as Ozempic, has become increasingly prevalent in the management of type 2 diabetes and obesity.1 Initially intended for treating type 2 diabetes, these drugs are now being used more frequently for weight loss. GLP-1 drugs have demonstrated promising results in improving glycemic control, promoting weight loss, and reducing cardiovascular risks. However, there is limited research on how Canadians perceive and utilize these medications in their daily lives.
Media contact:
Sylvain Charlebois, Scientific Director, Agri-Food Analytics Lab
Dalhousie University
sylvain.charlebois@dal.ca
902-222-4142 (cell)
Download the report: